Healthcare / Medical DevicesNasdaqCM
$0.70
-0.07 (-9.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.9M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-666.2%
↓Gross Margin
62.0%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-131.8%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.3M · net income $-17.5M · FCF $-10.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $8.3M | $8.3M | $8.7M | $8.9M | $8.5M | $7.9M | $7.4M | $5.5M | $5.0M | $3.6M | $1.3M | $59000.00 | $295000.00 | $59000.00 | $0.00 | — |
| Net Income | $-17.5M | $-17.5M | $-11.2M | $-20.2M | $-14.5M | $-19.6M | $-15.8M | $-18.1M | $-17.0M | $-13.4M | $-15.8M | $-26.6M | $-25.6M | $-21.8M | $-14.1M | $-16.2M |
| EBITDA | $-6.5M | $-6.5M | $-5.2M | $-16.4M | $-4.9M | $-19.0M | $-16.7M | $-17.9M | $-16.8M | $-14.0M | $-15.0M | $-25.6M | $-25.5M | $-22.7M | $-14.7M | $-16.5M |
| EPS | -25.39 | -25.39 | -353.22 | -16934.40 | -947.80 | -419479.20 | -1568490.00 | — | — | — | — | — | — | — | — | — |
| Gross Margin | 62.0% | 62.0% | 64.9% | 56.2% | 55.7% | 56.7% | 54.5% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -134.3% | -134.3% | -125.7% | -198.9% | -201.0% | -246.5% | -228.8% | -328.5% | -340.9% | -416.9% | -1215.1% | -43996.6% | -8741.4% | -38764.4% | — | — |
| Net Margin | -211.9% | -211.9% | -127.7% | -228.0% | -170.0% | -246.9% | -212.8% | -328.7% | -340.8% | -376.6% | -1225.1% | -45055.9% | -8673.6% | -36878.0% | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.12 | 0.12 | 0.08 | 0.24 | 0.08 | — | — | — | — | — | — | 0.32 | — | — | — | — |
| Current Ratio | 1.56 | 1.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-10.9M | $-10.9M | $-9.7M | $-18.2M | $-15.3M | $-18.1M | $-16.9M | $-16.9M | $-14.8M | $-12.2M | $-16.4M | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | -666.2% | -666.2% | -171.0% | -629.4% | -117.5% | -75.4% | -97.0% | -910.3% | -286.9% | -82.4% | -898.8% | -218.4% | -87.6% | -42.1% | -108.6% | -352.4% |
| Valuation | ||||||||||||||||
| P/B | 0.18 | 0.18 | 0.24 | 0.36 | 0.36 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -5.4% | -5.4% | -1.4% | 3.8% | — | 6.5% | 35.0% | 10.3% | 40.7% | 175.6% | 2084.7% | -80.0% | 400.0% | — | — | — |
| EPS Growth | 92.8% | 92.8% | 97.9% | -1686.7% | — | 73.3% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-98.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-353.22 → -25.39
Residual
-98.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.